The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is ...

Molecular imaging and theranostics enhance oncologic management via integrated diagnostic and therapeutic modalities. Amid the dynamic and increasingly complex oncologic landscape, the Common Sense ...

Prostate cancer (PCa) is a leading cause of cancer deaths, making effective early detection, precise staging, and monitoring of biochemical recurrence crucial. Next-generation prostate-specific ...

Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals ...

Whole-body CD8+ T-cell PET imaging can detect spatial and temporal localization of CD8+ T cells. To obtain insight into early CD8+ T-cell response to immunotherapy in patients with melanoma, a highly ...

The objective of this study is to describe the prevalence of inflammatory cardiopulmonary findings in a prospective cohort of long coronavirus disease (LC) patients. Methods: Subjects with a history ...

Our objectives were to assess the prognostic value of posttherapy [177Lu]Lu-PSMA (LuPSMA) SPECT/CT by visual evaluation using RECIP 1.0 during LuPSMA therapy and develop an evidence-based clinical ...

The PSMA-PET Registry for Recurrent Prostate Cancer study was initiated in Ontario, Canada, to provide access to and characterize the performance of 18F-prostate-specific membrane antigen (PSMA) ...

Quantitative 18F-FDG PET is increasingly being recognized as an important tool for diagnosis, determination of prognosis, and response monitoring in oncology. However, PET quantification with, for ...

Results from a new PET/CT scanner using lutetium-yttrium oxyorthosilicate (LYSO) crystals for the PET component are presented. This scanner, which operates in a fully 3-dimensional mode, has a ...

Animal models have been instrumental in elucidating key biochemical and physiologic processes of cancer onset and propagation in a living organism. Most importantly, they have served as a surrogate ...

Quantitative [89 Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI ...